These observations strongly argue for TPE in contemporary cancer therapy regimes, aimed at reducing tumor driving EVs, especially those containing well established and TPE depletable disease biomarkers such as PD-L1 (Figure 5). The gene discussed is CD274; the disease is neoplasm.